Target Health Unveils Target Document® Version 1.5

Target Health Unveils Target Document® Version 1.5

NEW YORK --(Business Wire)--
Target Health Inc., an industry-leading eCRO, has announced the release of Target Document® version 1.5. Target Document® is a cost-effective, distributable, secure, user-friendly, 21 CFR Part 11 compliant, Internet-based, document sharing, distribution, and management system that allows users in any industry, depending on their roles and permissions, to post, share, electronically sign, and archive any electronic document within a Web browser. New features include advanced user management, access to recycle bin, parallel sign off of documents, manual backup of any folder, configuration of e-Signature text, document expiration dating, email alerts to all users, etc. According to Jules Mitchel, MBA, Ph.D., President of Target Health, "Target Document® eliminates the need to manage and distribute documents via email, saves paper and is ideal for vendors, CROs, clinical rsearch sites, and Sponsors who want to transparently communicate among themselves in a secure environment. Dr. Mitchel added that in pharmaceuticals, "Target Document® allows for a paperless Trial Master File (TMF) and is part of the paperless eClinical toolbox of products available from Target Health." The Target Health toolbox includes: Target e*CRF®, Target Health's flagship EDC software, which has been used in over 200 clinical trials, including 18 regulatory approvals; Target Encoder® - which links directly into the Target e*CRF® database to encode MedDRA and WHODRUG terms; Target e*CTMSTM (Clinical Trial Management System)- which allows for Internet-based project management, across studies at one website ; and Target Newsletter® - which allows for a clinical trial newsletter with real time enrollment data and comments.

About Target Health Inc.

Established in 1993, Target Health Inc. has been providing advanced clinical trial technology for more than a decade. As a full service CRO, the company is dedicated to all aspects of regulatory affairs, clinical research, biostatistics, data management, strategic planning, and drug device development. The company's client list is comprised of some of the most highly respected pharmaceutical companies as well as smaller biotechnology firms. Target Health is based in New York, NY.

For more information about Target Health and Target Document, go to

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.